Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. - Wikidata - awgldk - TriplyDB

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

http://www.wikidata.org/entity/Q33884913

about

Emerging utility of once-weekly exenatide in patients with type 2 diabetes Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus Exenatide once weekly: opportunities in the primary care setting.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis.Potential use of exenatide for the treatment of obesity.Pharmacotherapy for childhood obesity: present and future prospects.Exenatide extended-release; clinical trials, patient preference, and economic considerations.Evolution of exenatide as a diabetes therapeutic.Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes.Exenatide extended-release: a review of its use in type 2 diabetes mellitus.Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.Once weekly exenatide: efficacy, tolerability and place in therapy.Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.Long-term tolerance and efficacy of adjunctive exenatide therapy on glycaemic control and bodyweight in type 2 diabetes: a retrospective study from a specialist diabetes outpatient clinic.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Once-weekly exenatide as a treatment for Type 2 diabetes.Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.

P2860

Q26777320-ECD0481D-5697-499F-99B0-6B3CAF70F59A Q28088578-D8994956-6382-49FC-B5A2-71F76712854A Q30431639-1535EE50-E77C-484F-8806-8A4F98CF6746 Q30643065-120C22EF-60F4-4018-9263-B2E47EC14DF9 Q31066859-AADB6429-92B1-4362-9134-EF5C6F1A1A24 Q33824522-03D96412-A6CA-4577-A227-399015B92836 Q35906506-2CA39E70-7A0C-4C96-AEB2-0F9F9DF4E608 Q35940436-62B47804-0071-4918-8D18-C36D3159C3B2 Q36391466-8B638C47-99A1-4D6B-B908-FD25067032ED Q36468087-B4F943F8-B994-4280-85FC-8BFEF7493FAA Q36538817-3E57314A-4A03-4B09-B14D-270839490763 Q36877205-A872A7E4-61A7-4F75-B43D-447974D9C328 Q37106564-644B4CB0-B4D0-46F4-8272-F38909A6150D Q37446672-66007390-5AFC-42BE-BBC0-BE7D6191803B Q37974632-6E99F77E-8BCC-422A-9DAB-6F26031FEE31 Q37992255-92166C0A-974B-4892-86C9-A377EE8689C5 Q38016390-84299C46-225D-47E4-B144-C222C83EE95F Q38020941-98D6928B-2EC4-4FE4-B74B-AA01E72EF182 Q38032321-250A7428-6EC6-47DA-9D6B-C5B174639CA3 Q38065321-5DE78CBF-EAC0-447E-8C22-FDB12B9CDD2B Q38083112-F7102EB9-B5E9-42C5-B05B-782926A089C6 Q38095813-736BC80E-7D8A-4A48-8412-D3C1143AED2A Q38216039-3EAB2159-8DE2-49D8-914C-F24AB04585C4 Q38286444-FA03A917-4FAF-4830-ABCF-071F8C51D155 Q38497691-95DEF1A2-48A4-44EF-B9A0-74186196A9A5 Q38526870-4AA4E9ED-60CB-4F58-B03D-7C9811AB1A86 Q38602769-CBF86441-F0D6-40FA-85BD-E8228ADCC350 Q38885174-65A2426A-E445-4D79-9A56-9B5C6A77C951 Q39489588-DC184FE7-A3F2-43E0-BCB6-D4DF04DCD70D Q42091988-EEFD4D50-9871-4000-BE6B-52A31C30E1B8 Q48228283-86040C85-0654-43DC-8EF1-FFE9E79774B7

P2860

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

http://www.wikidata.org/entity/Q33884913

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@ast

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@en

type

label

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@ast

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@en

prefLabel

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@ast

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@en

P1433

Q33884913-05D63672-1AEC-40ED-B47F-4C381EC4BCCB

P1476

Q33884913-461ABFAE-AAD0-47FA-878B-A0E0E84D7E91

P2093

Q33884913-2CD97340-1E5C-4E04-ABFF-819B6498CDF1

Q33884913-2D8D290E-463D-455E-96C6-8D2D68A6091E

Q33884913-5F63C787-77CE-4C7A-8678-CEF2ACDAB322

Q33884913-64642EA8-75FF-4738-8382-1EDFC2BE6D27

Q33884913-701E3CB5-9643-40D3-A550-AF551A13A3C6

Q33884913-8FD88E11-4D81-466B-A673-165935954CFF

P2860

Q33884913-07E9F81B-922A-4F7F-BD98-86FBCDC8C975

Q33884913-09A5D402-5B6A-4C3C-B09B-CFAA14573211

Q33884913-0F2E7329-3769-47C6-AE41-00AC1E9F775C

Q33884913-1450B6B6-198E-43D5-BA10-B02097C7E900

Q33884913-16AFB132-D674-493D-AEFB-4B6198EEE14C

Q33884913-1B748610-0FEC-448E-B2AC-FBDD3D5DA3F3

Q33884913-201DA851-F948-476A-9DF8-EBE0F833340D

Q33884913-20E09FE1-24C3-49D9-A803-50D967D15097

Q33884913-218E7520-D500-4FE7-844A-B873E73E7A24

Q33884913-247F09A8-866C-4E61-B99A-C2B74DCFAA37

P2888

Q33884913-9B5FD195-1686-40CD-89FB-096F2226B36E

P304

Q33884913-D7E47CBD-ED70-420F-BB44-6E061ABFEF41

P31

Q33884913-97D12F9A-48B2-4A53-AE5E-685C2B573554

P356

Q33884913-17C214A0-44AF-466F-ABC2-5E59594F34FC

P478

Q33884913-26E49BC0-ECB7-4A2A-8013-234DCFB2F25D

P577

Q33884913-365524EF-26DD-4FAC-8C1C-DDDF4DA4258A

P5875

Q33884913-5B295731-A456-4612-9CAD-E8CBF811A3C3

P6179

Q33884913-1D78311A-100D-4E75-8F1B-6E3AC4C6B477

P698

Q33884913-6F31D8D6-2045-4336-8491-5C6E945E7AE9

P932

Q33884913-927ABADD-4FB7-49AF-A930-F396A58852F8

P356

P1433

BMC Endocrine Disorders

P1476

Exenatide once weekly treatmen ...... and weight loss over 2 years.

@en

P2093

Brandon Walsh

http://www.w3.org/2001/XMLSchema#string

Jenny Han

http://www.w3.org/2001/XMLSchema#string

Kate Gurney

http://www.w3.org/2001/XMLSchema#string

Kristin Taylor

http://www.w3.org/2001/XMLSchema#string

Michael Trautmann

http://www.w3.org/2001/XMLSchema#string

Richard Pencek

http://www.w3.org/2001/XMLSchema#string

P2860

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Nutrition recommendations and interventions for diabetes--2006: a position statement of the American Diabetes Association

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

P2888

P304

9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1472-6823-11-9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51085850

http://www.w3.org/2001/XMLSchema#string

P6179

1036358018

http://www.w3.org/2001/XMLSchema#string

P698

21529363

http://www.w3.org/2001/XMLSchema#string

P932

3112417

http://www.w3.org/2001/XMLSchema#string